9 High-Risk Stocks to Buy for Massive Rewards
[Editor’s note: This story was previously published in November 2018. It has since been updated and republished.]
Slow and steady wins the race, as the old adage goes. But slow and steady can be a bit boring. Investors looking for stocks to buy, as a rule, should focus on high-quality, and preferably, lower-risk issues.
Still, there’s room in any investor’s portfolio for higher-risk, higher-reward plays — as long as those risks are understood.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
In that vein, here are 10 stocks to buy that offer potentially significant rewards … and almost as much risk. None of these stocks should be a core part of a portfolio, and all have the potential to blow up in your face.
- 10 Dow Jones Stocks Holding the Blue Chip Index Back
But taking those risks also creates the possibility of a major reward. It’s likely at least a few of these stocks will wind up big winners going forward.
Teva Pharmaceutical (TEVA)
Teva Pharmaceutical (NYSE:TEVA) isn’t having a great year, down just about 7%.
Teva has too much debt and too little growth. Its key drug, Copaxone, which treats multiple sclerosis, is facing generic competition from Mylan (NASDAQ:MYL), among others. Bankruptcy likely isn’t a near-term scenario but the current trajectory suggests it could occur down the line. In short, TEVA is a classic contrarian, “buy when there’s blood in the streets†type of play. And there are reasons TEVA is one of these great (if risky) stocks to buy.
While pressure has persisted on generic drugs, but it won’t last forever.
The company has sold assets to clean up its balance sheet, which has de-risked the story somewhat. In my opinion, Teva is a better version of Valeant, but with an easier path back to normalcy.
It’s a risky path, but if it works TEVA could gain another 20%-plus simply by reaching a higher multiple and removing bankruptcy fears.
Source: Shutterstock
Scientific Games Corp (SGMS)
The story already has played out somewhat at Scientific Games (NASDAQ:SGMS), which is up 14.23% so far this year. But the growth story isn’t necessarily over.
Only a few years ago, Scientific Games was a sleepy, low-growth provider of lottery tickets and terminals. But in quick succession, SciGames acquired slot machine manufacturers WMS Industries and Bally Technologies, the latter coming only months after Bally bought equipment maker and gaming table designer Shuffle Master. Scientific Games became the dominant supplier to the casino industry worldwide: a “one-stop shop†for casino floors.
It also became one of the most indebted companies in the U.S. markets and still is. The combination of that debt and careful cost controls at casinos, particularly in the U.S., kept SGMS stock below $20 to start the year.
- 8 Risky Stocks to Watch as Earnings Season Kicks Off
But it now looks like the long-awaited “replacement cycle†of slot machines is arriving and that could be hugely beneficial for Scientific Games and its smaller, similar rival Everi Holdings Inc (NYSE:EVRI). And considering how much leverage is still on the balance sheet, there’s a case for SGMS to clear $100 — yes, $100 — if profit growth accelerates.
That’s not a guarantee, obviously, but it’s the nature of highly indebted companies. Leverage is a weight when those companies struggle, and it’s a springboard when they grow.
Source: Chesapeake Energy
Chesapeake Energy (CHK)
In the case of Chesapeake Energy Corporation (NYSE:CHK), leverage has been a weight. After optimism about stable energy prices and Chesapeake’s improved balance sheet boosted CHK stock in 2017, it was nothing but downhill in 2018. CHK now trades up ,pre than 57% since the beginning of the year. This could be the upswing you’ve been waiting for.
I think CHK is the best, if riskiest, of the stocks to buy on higher energy prices. At the least, Chesapeake has bought itself more time for those prices to work higher. It’s also worth pointing out that Chesapeake bonds actually have been rather stable so far this year. Efficiency improvements at the wellhead have lowered costs as well.
Chesapeake is a risky play, but the combination of debt on the balance sheet and leverage from higher energy prices mean that with a couple of changes, CHK could soar.
Source: Web Summit Via Flickr
Splunk (SPLK)
Splunk (NASDAQ:SPLK), on the other hand, isn’t the cheapest stock in its space or anywhere else. The high-flying “operational intelligence†software provider trades up nearly 30% since the beginning of the year alone.
The valuation alone shows the risk in SPLK, which has pulled back from brief early-2014 highs above $100. But since that pullback, SPLK stock actually has been rather stable, as investors give the company time to grow into its valuation.
Meanwhile, Splunk continues to be a likely acquisition target, with Cisco (NASDAQ:CSCO) cited as a potential buyer in June and International Business Machines (NYSE:IBM) long thought to be a logical acquirer.
- 7 High-Risk Stocks With Big Potential Rewards
Splunk is a classic growth stock in that it, too, is high-risk and high-reward. But it looks like one of the better growth stocks to buy in what might be an over-aggressive market at the moment.
Source: Shutterstock
Ship Finance International (SFL)
The shipping space generally has been a “Bermuda Triangle†for investor capital, but Ship Finance International (NYSE:SFL) might be the exception to the rule.
There’s likely to be some near-term volatility and Ship Finance’s dividend, which currently yields 10.95%, could be at risk, but it’s still one of those great stocks to buy if you can handle the risk.
But this also remains one of the best plays in shipping, available for a modest premium to book value and at low-teens multiple to earnings. The industry alone, and a heavily leveraged balance sheet, both show the risk.
But if Ship Finance can make it through some choppy waters over the next few months, there’s likely a nice return for shareholders on the other side.
GW Pharmaceuticals (GWPH)
There’s no sector of the market more boom-and-bust than biotech and drug development. GW Pharmaceuticals (NASDAQ:GWPH) doubles down on that volatility by developing its drugs from marijuana.
But GW Pharmaceuticals isn’t one of those fly-by-night penny stocks to buy based on legalized weed. It’s a $2.6 billion pharmaceutical company with a legitimate lead product candidate in Epidiolex, aimed to treat Dravet Syndrome and Lennox-Gastaut Syndrome. Sativex, used to treat multiple sclerosis
Sativex, used to treat multiple sclerosis spasticity, already is on the market. And another compound has potential uses to fight epilepsy and treat autism spectrum disorders.
- 10 Medical Marijuana Stocks to Cure Your Portfolio
Like most drug development plays, GWPH is high-risk. But there’s reason for investors to hold long-term optimism toward the company’s pipeline. Success in getting those drugs to market likely would make GWPH an acquisition target at some point suggesting a significant upside from current levels. If it happens, analysts see GWPH stock surging near 30%.
That in turn, would suggest likely significant upside from current levels for GWPH stock.
Source: Shutterstock
Canadian Solar (CSIQ)
- 1